USPTO Added Too Little Time To Supernus Patent, Suit Says
The U.S. Patent and Trademark Office did not extend the life of a patent for the pulmonary arterial hypertension drug Orenitram long enough after it took too long to consider Supernus...To view the full article, register now.
Already a subscriber? Click here to view full article